FDA granted Breakthrough Therapy Designation to EBV-CTL for the treatment of Epstein-Barr Virus following transplant of bone marrow stem cells.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
